Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

752
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
752
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

196
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
196
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

5.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
5.2K
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

294
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
294
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy.

Leukemia research·2026
Same author

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Research square·2025
Same author

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Transplantation and cellular therapy·2025
Same author

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.

Blood neoplasia·2025
Same author

The Aza/Ven reshuffle.

Blood·2024
Same author

Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition.

Leukemia·2024

Related Experiment Video

Updated: Jan 9, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K

Post-HCT maintenance therapy for AML: who, when, why, how long?

Mark Levis1

  • 1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.

Hematology. American Society of Hematology. Education Program
|December 5, 2025
PubMed
Summary

Allogeneic hematopoietic cell transplantation (HCT) is crucial for acute myeloid leukemia (AML) patients. However, post-HCT maintenance therapy lacks strong evidence, despite its use, highlighting a need for further research.

More Related Videos

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.9K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

604

Related Experiment Videos

Last Updated: Jan 9, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.3K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.9K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

604

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Allogeneic hematopoietic cell transplantation (HCT) is a key curative therapy for acute myeloid leukemia (AML) to prevent disease relapse.
  • Despite HCT's effectiveness, relapse remains a concern, leading to the use of post-HCT maintenance therapy.
  • The evidence supporting the efficacy of most post-HCT maintenance therapies in AML is limited or lacking.

Purpose of the Study:

  • To review the existing data, or lack thereof, supporting the use of post-HCT maintenance therapy in AML.
  • To discuss the potential benefits and pitfalls of using molecularly targeted drugs for maintenance therapy after HCT in AML patients.
  • To provide a critical evaluation of current practices in AML post-HCT maintenance.

Main Methods:

  • Literature review of randomized controlled trials and clinical studies.
  • Analysis of data on molecularly targeted drugs, including FLT3 inhibitors.
  • Evaluation of evidence supporting the use of maintenance therapy in the context of HCT for AML.

Main Results:

  • Randomized data supports the use of FLT3 inhibitors as maintenance therapy in select AML patients post-HCT.
  • Evidence for other drug classes used in post-HCT AML maintenance is currently insufficient.
  • The practice of offering maintenance therapy is common, but often not based on robust clinical trial data.

Conclusions:

  • While FLT3 inhibitors show promise, robust evidence for other maintenance therapies post-HCT in AML is still needed.
  • Clinicians continue to use maintenance therapy hoping to improve outcomes, necessitating a careful consideration of available data.
  • Further research is required to establish the efficacy and safety of various maintenance strategies in AML patients undergoing HCT.